ACP
CRSP icon

Acuta Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Acuta Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-134,000
Closed -$5.49M – 42
2019
Q3 		$5.49M Buy
134,000
+55,000
+70% +$2.63M 3.96% 9
2019
Q2 		$3.72M Buy
+79,000
New +$3.16M 1.32% 23

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Acuta Capital Partners's CRSP Position: Q4 2019 in Review

Acuta Capital Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2019, closing a stake of 134,000 shares — an estimated $5.49M sold.

Acuta Capital Partners first reported a position in CRSP in Q2 2019 and held it in 2 quarters. The position peaked at $5.49M in Q3 2019. 253 funds tracked by Wall St. Rank hold CRSP as of Q4 2019.

  • Acuta Capital Partners reported no remaining CRISPR Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Acuta Capital Partners sold 134,000 CRISPR Therapeutics shares in Q4 2019, an estimated $5.49M.
  • Acuta Capital Partners first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 2 quarters.
  • Acuta Capital Partners's CRISPR Therapeutics position peaked at $5.49M in Q3 2019.
  • 253 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2019.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.